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PURPOSE. The purpose of this study is to determine the potential of narrow spectrum kinase
inhibitors (NSKIs) to treat inflammatory eye disorders.
METHODS. Human conjunctival epithelial (HCE) cells were retrieved from subjects via
impression cytology. Real-time quantitative PCR (qPCR) was performed on HCE cells to
determine gene expression of NSKI kinase targets and proinflammatory cytokines in dry eye
disease (DED) patients versus healthy controls. qPCR also assessed p38a expression in
hyperosmolar-treated Chang conjunctival epithelial cells. Interaction of NSKI TOP1362 with
the kinases was evaluated in ATP-dependent Z-LYTE and competition binding assays. Anti-
inflammatory activity was assessed in human peripheral blood mononuclear cells and primary
macrophages. In an endotoxin-induced uveitis (EIU) study, lipopolysaccharide (LPS) was
administered intravitreally to Lewis rats. TOP1362, dexamethasone, or vehicle was
administered topically, and inflammatory cytokine levels were measured 6 hours after LPS
injection.
RESULTS. HCE cells from DED patients showed significantly increased expression of p38a,
spleen tyrosine kinase (Syk), Src, lymphocyte-specific protein tyrosine kinase (Lck),
interleukin one beta (IL-1b), interleukin eight (IL-8), monocyte chemotactic protein-1
(MCP-1), and matrix metalloproteinase-9 (MMP-9). TOP1362 strongly inhibited the kinase
targets p38a, Syk, Src, and Lck, blocked the rise in p38a expression in hyperosmolar Chang
cells, and potently reduced inflammatory cytokine release in cellular models of innate and
adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-
induced rise in inflammatory cell infiltration and ocular cytokine levels with efficacy
comparable to that of dexamethasone.
CONCLUSIONS. TOP1362 is a potent inhibitor of kinases upregulated in DED and markedly
attenuates proinflammatory cytokine release in vitro and in vivo, highlighting the therapeutic
potential of NSKIs for treating ocular inflammation, such as that observed in DED.
Keywords: kinase inhibitor, dry eye disease, endotoxin-induced uveitis, inflammation
Dry eye disease (DED) is a chronic, multifactorial inflamma-tory disorder of the lacrimal functional unit characterized
by pain, visual disturbances, tear film instability, and, in severe
cases, blindness.1,2 This disorder is associated with aging,
contact lens wear, refractive surgery, and immune diseases, and
it affects 15% to 30% of those over 50, depending on
ethnicity.3,4 Current therapies for treating DED are unsatisfac-
tory. Until recently, the only approved therapy for DED was
Restasis (Allergan, Irvine, CA, USA), a product whose active
ingredient is the immunosuppressant cyclosporin A (CsA).5,6
This treatment has limited efficacy, tolerability issues, and a
slow onset of action and is licensed for treating signs of the
disease only. Corticosteroids are commonly prescribed and are
effective on both signs and symptoms of DED. However, these
drugs are restricted to short-term use as a consequence of the
serious ocular adverse effects they produce.7 Recently, a new
therapy, Xiidra (Shire US, Lexington, MA, USA), containing the
active ingredient lifitegrast,8 has been approved for treating
both the signs and symptoms of DED, but this agent also has
limited efficacy and commonly occurring toleration issues.9
Consequently, an unmet medical need still exists10 for an
innovative, fast-acting, effective, safe, and well-tolerated immu-
nomodulatory therapy to address both the signs and symptoms
of DED.
Several studies indicate that both tear film hyperosmolarity
and ocular surface inflammation11,12 play crucial roles in the
initiation and progression of DED.13,14 The evidence for an
inflammatory response in the disease is provided by the
presence of inflammation-related markers, including interleu-
kin one beta (IL-1b), interleukin six (IL-6), interleukin eight (IL-
8), interferon gamma (IFN-c), matrix metalloproteinase-9 (MMP-
9), tumor necrosis factor alpha (TNF-a), and monocyte
chemotactic protein-1 (MCP-1), in tear fluids and conjunctival
epithelia from patients with DED.15–25 Kinases are key
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mediators of cytokine production26 and ocular surface stress.27
As such, various inhibitors of these enzymes elicit anti-
inflammatory effects in preclinical models of DED.28,29 The
efforts in developing kinase inhibitors to treat ocular inflam-
mation have culminated with the topical ophthalmic Janus
kinase (JAK) inhibitor tofacitinib30–32 and the dual JAK–Syk
inhibitor33 prodrug R348 being advanced into the clinic as
potential therapies for DED.
Narrow spectrum kinase inhibitors (NSKIs) are a novel
class of pharmacologic agents that simultaneously target key
kinases involved in both innate and adaptive immune cell
signaling, namely, mitogen activated protein kinase (MAPK)
p38a, spleen tyrosine kinase (Syk), and Src family kinases
(SFK), including Src and lymphocyte-specific protein tyrosine
kinase (Lck). Recent studies have highlighted the potential of
NSKIs in alleviating inflammatory conditions such as ulcera-
tive colitis (UC),34 chronic obstructive pulmonary disease,
(COPD),35 and arthritis.36 Little is known, however, about the
expression of NSKI targets in DED, with the exception of
MAPK p38a, which is upregulated by hyperosmolarity and
desiccating stress in preclinical models.37–41 Although not
directly investigated hitherto, Lck and Syk are likely to be
involved in the known role of T cells in DED pathogene-
sis,12,42 a hypothesis supported by the fact that currently
approved therapies for DED, Restasis and Xiidra, target T
cells. Therefore, NSKIs offer a novel approach to target
simultaneously both the early stages (hyperosmolarity and
desiccating stress of the ocular surface) and the latter stages
(dysregulated T-cell response) of DED. Here, we reveal, for
the first time, increased expression of NSKI targets p38a, Syk,
and SFK in conjunctival impression cytology (CIC) cells from
DED patients, which coincides with raised levels of inflam-
matory markers. Accordingly, we demonstrate that
TOP1362—which combines p38a, Syk, and SFK inhibitory
activities within a single molecular framework—exerts potent
anti-inflammatory effects in both in vitro and in vivo models
of inflammatory eye disease, giving rise to the premise that
NSKIs could be used to treat disorders characterized by
chronic inflammation, such as DED.
MATERIALS AND METHODS
Subjects
The study was performed in line with research ethics
permission received from GCU Life Sciences Ethics Committee
(April 2014, LS1333). Informed consent was obtained from
each subject. Classification of the ocular surface status of
subjects was determined from the outcome of three measure-
ments, namely ocular surface disease index (OSDI43,44),
noninvasive tear break-up time (NITBUT45), and the Schirmer
1 test.46 Control subjects provided OSDI scores of <10,
NITBUT of ‡10 seconds, and Schirmer strip wetting length of
‡10 mm. Subjects providing OSDI scores, NITBUT, and
Schirmer 1 test results outside of these ranges were classed
as DED (Table 1). CIC (bulbar conjunctiva) was performed on
10 healthy controls (mean age, 35 6 13 years) and 9 DED
subjects (mean age, 44 6 19 years).
Cell Culture
The ‘‘Chang’’ human conjunctival cell line (Wong–Kilbourne
derivative of Chang conjunctiva, clone 1-5c-4; ATCC, Mana-
ssas, VA, USA; certified cell line [CCL]-20) was cultured in
standard conditions (5% CO2, 95% humidified atmosphere, at
378C) in complete media: Dulbecco’s modified Eagle Gluta-
MAX medium (DMEM) enriched with 10% (v/v) heat-treated
fetal bovine serum (FBS), penicillin (50 U/mL), and strepto-
mycin (50 U/mL; all Thermo Scientific, Gillingham, United
Kingdom). Cells were maintained weekly by passaging
(subculturing) with 0.25% v/v trypsin–EDTA at a 1:3 ratio to
maintain cell confluency.
For hyperosmolarity assays, cells were seeded at a density of
13 105 cells per well in 12-well culture plates and allowed to
grow to 50% to 60% confluency. Cells were then treated for 6
hours with hyperosmolar solutions of NaCl (100 and 400 mM)
or sucrose (200 and 400 mM) to determine the most suitable
hyperosmolar conditions. Quantitative PCR (qPCR) assays
were carried out, and results were analyzed using the DCT
method, 2(DCT) ¼ (CT target gene – CT GAPDH), where glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was the chosen
TABLE 1. Clinical Data of Subjects Who Participated in Study
Sex Age, y OSDI NITBUT, s Schirmer, mm Eye Sampled
DED (D) or
Control (C) Treatment
Female 31 31.8 5 4 Right D Preservative-free eyedrops
Female 22 22.7 5 8 Right D Eyedrops with preservative
Female 44 20.8 7 0 Right D Contact lens rewetting drops
Female 53 20.8 4 0 Right D None
Male 43 16.7 7 4 Right D Eyedrops with preservative
Female 42 14.6 6 2 Right D None
Female 27 15.0 4 5 Right D Eyedrops with preservative
Male 50 27.1 6 8 Right D Preservative-free eyedrops
Female 86 13.9 5 8 Right D Preservative-free eyedrops
Female 23 4.2 14 27 Right C None
Female 24 6.3 14 10 Right C None
Male 20 0.0 12 13 Right C None
Female 32 4.5 12 35 Right C None
Male 57 0.0 11 20 Right C None
Female 57 6.8 11 13 Right C None
Female 42 8.3 10 25 Left and right C None
Male 36 0.0 11 16 Right C None
Female 31 4.2 38 30 Right C None
Male 29 6.3 12 10 Right C None
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housekeeping gene. Target genes were standardized to
GAPDH. Assays were carried out in triplicate.
Eyeprim Sample Collection
Human conjunctival epithelial cells (HCEs) were retrieved
from healthy controls (n¼ 10) and subjects with DED (n¼ 9),
using the Eyeprim device (Opia Technologies, Paris, France).
Membranes were transferred to sterile eppendorf tubes with
RLT (RNA lysis buffer; Qiagen, Manchester, United Kingdom)
containing b-mercaptoethanol and stored at 808C until
processing for RNA extraction. Two presses per membrane
were taken each at temporal and inferior conjunctiva of
subjects.
Total RNA Extraction
Total RNA was extracted from Chang cells and human CIC
samples with the QIAshredder and RNeasy Mini Kit (Qiagen)
following the manufacturer’s instructions. Total RNA, extracted
from Chang cells (63 106 cells/mL) and human CIC samples,
was quantified and assessed for purity with the NanoDrop
spectrophometer (Thermo Scientific).
Reverse Transcription of Total RNA
Complementary DNA (cDNA) was synthesized from total RNA
and extracted with the RT2 First Strand Kit (Qiagen), following
the manufacturer’s instructions. Synthesized cDNA was stored
at 208C until required for qPCR analysis.
Real-Time PCR
Details of the primers used (Qiagen) are provided in Table 2.
The qPCR was carried out as follows for one reaction: 12.5
lL RT2 SYBR Green Mastermix (Qiagen), 1 lL RT2 qPCR Primer
Assay (10 lM stock; Qiagen), 10.5 lL RNase-free water
(Qiagen), and 1 lL cDNA template (500 ng/lL, unless
otherwise stated) for both Chang cells and human CIC
samples. Reactions were performed in duplicate using 96-well
plates (Thermo Scientific). RNase-free water was used as
negative template controls. Using the ABI 7500Viia qPCR
machine (Applied Biosystems, Warrington, United Kingdom; or
Bio-Rad, Hercules, CA, USA), the PCR reaction was incubated
at 958C for 15 minutes, followed by 39 cycles of 958C for 15
seconds, and 608C for 20 seconds, and then the plate was read.
A dissociation curve, involving the incubation of the formed
product for an additional 30 minutes at 608C, was generated to
ensure only one specific product was obtained. For these
assays, GAPDH was chosen as the housekeeping gene to which
all target genes were normalized. Results were analyzed using
the DCT method, as mentioned above.
Statistical Analyses
Results are presented from three independent experiments,
unless stated otherwise, and are shown as mean 6 SEM.
Statistical analyses were performed using GraphPad Prism V
software (GraphPad, La Jolla, CA, USA). Student’s t-test (two-
tailed) and Dunnett tests were performed.
Ligand Dissociation Kinase Assay
Kinase-tagged T7 phage strains were prepared in an Esche-
richia coli host derived from the BL21 strain. E. coli were
grown to log-phase and infected with T7 phage and incubated
with shaking at 328C until lysis. The lysates were centrifuged
and filtered to remove cell debris. The remaining kinases were
produced in HEK-293 cells and subsequently tagged with DNA
for qPCR detection. Streptavidin-coated magnetic beads were
treated with biotinylated small molecule ligands for 30 minutes
at room temperature to generate affinity resins for kinase
assays. The liganded beads were blocked with excess biotin
and washed with blocking buffer (SeaBlock; [Pierce Biotech-
nology, Rockford, IL, USA], 1% BSA, 0.05% Tween 20, 1 mM
dithiothreitol [DTT]) to remove unbound ligand and to reduce
nonspecific binding. Binding reactions were assembled by
combining kinases, liganded affinity beads, and test com-
pounds in 13 binding buffer (20% SeaBlock, 0.173 PBS, 0.05%
Tween 20, 6 mM DTT). Test compounds were prepared as 111-
fold stocks in 100% dimethyl sulfoxide (DMSO). Kds were
determined using an 11-point threefold compound dilution
series with three DMSO control points. All compounds for Kd
measurements are distributed by acoustic transfer (noncontact
dispensing) in 100% DMSO. The compounds were then diluted
directly into the assays such that the final concentration of
DMSO was 0.9%. All reactions were performed in polypropyl-
ene 384-well plates at a final volume of 0.02 mL. The assay
plates were incubated at room temperature with shaking for 1
hour, and the affinity beads were washed with buffer (13 PBS,
0.05% Tween 20). The beads were then resuspended in elution
buffer (13 PBS, 0.05% Tween 20, 0.5 lM nonbiotinylated
affinity ligand) and incubated at room temperature with
shaking for 30 minutes. The kinase concentration in the
eluates was measured by qPCR.
Substrate Phosphorylation Kinase Assay
A commercial 384-well fluorescence resonance energy transfer
(FRET)-based kinase assay for p38a, Syk, and Src kinases was
used to measure inhibitory activity of substrate phosphoryla-
tion. TOP1362 or vehicle (DMSO, 1% v/v) was incubated with
the kinase of interest (p38a, 50 ng/mL; Syk, 500 ng/mL; or Src,
750 ng/mL) for 2 hours. Z-lyte peptide (Invitrogen, Paisley,
United Kingdom), selective for an individual kinase, was added
TABLE 2. Human Primers Used in qPCR Target Gene Analysis
Primer Catalog No. UniGene No. RefSeq Accession No. Band Size, bp
Reference
Position
p38a MAPK 330001 PPH00750B Hs.485233 NM_001315.2 90 690
Syk 330001 PPH01639F Hs.371720 NM_003177.5 119 1818
Src 330001 PPH00103C Hs.195659 NM_005417.4 131 1366
Lck 330001 PPH00185E Hs.470627 NM_005356.3 132 941
IL-1b 330001 PPH00171C Hs.126256 NM_000576.2 126 574
IL-8 330001 PPH00568A Hs.624 NM_000584.3 126 326
MCP-1 330001 PPH00192F Hs.303649 NM_002982.3 122 106
MMP-9 330001 PPH00152E Hs.297413 NM_004994.2 63 2107
GAPDH 330001 PPH00150F Hs.592355 NM_002046.5 130 842
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(Ser threonine 4 peptide for p38a, Tyr2 peptide for Syk and
Src). ATP, 10, 15, and 200 lM for p38a, Syk, and Src,
respectively, was then added. In addition, inactive MAPK-
activated protein kinase (MAPKAP) 2 (180 ng/mL) was added
to the p38a reaction mixture. After 1-hour incubation,
development reagent was added followed by an additional
hour of incubation. The reaction was terminated and read
using a fluorescence microplate reader.
Preparation of Human Peripheral Blood
Mononuclear Cells
Blood was diluted (1:1) with PBS-containing EDTA (2 mM)
before overlaying on Lymphoprep. The sample was centrifuged
(1200g, 20 minutes), and the resultant ‘‘buffy coat,’’ containing
the peripheral blood mononuclear cells (PBMCs), was collect-
ed. After further centrifugation (780g, 10 minutes) and
washing (32) in PBS containing EDTA (2 mM), the final cell
pellet was resuspended in 10 mL PBS/EDTA (2 mM)/BSA
(0.5%). Cells were counted, and the final concentration was
adjusted to 106 cells/mL by resuspension in RPMI 1640 culture
media containing heat inactivated FBS (10% v/v), penicillin/
streptomycin, and 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethane-
sulfonic acid (HEPES) (25 mM).
Cellular Assays
Lipopolysaccharide Stimulation of PBMCs. PBMCs (200
lL) were incubated (2 hours, 378C, 5% CO2) with test
compound (0.1 to 1000 ng/mL) or vehicle (DMSO, 0.5% v/v).
Lipopolysaccharide (LPS; 1 ng/mL) was added, and, after a 24-
hour incubation (378C, 5% CO2), plates were centrifuged
(780g, 2 minutes). Supernatants were collected for analysis of
IL-8 and TNF-a levels.
Anti-CD3/Anti-CD28 Stimulation of PBMCs. PBMCs
(200 lL) were added to anti-CD3 (clone OKT3, 0.6 lg/mL)
and anti-CD28 (clone CD28.2, 12 lg/mL) coated 96-well plates.
Compound (0.1 to 1000 ng/mL) or vehicle (DMSO, 0.5% v/v)
was added. After a 48-hour incubation (378C, 5% CO2), plates
were centrifuged (780g, 2 minutes), before the collection of
supernatants for analysis of IFN-c levels.
IFN-c Release From Anti-CD3/IL-2–Stimulated PBMC
Cells. PBMCs were added to a 96-well plate, and compound
(0.1 to 1000 ng/mL) was added 2 hours prior to stimulation
with a mixture of monoclonal antibody to CD3 (1 lg/mL;
FIGURE 1. (A) Structure of TOP1362. (B) p38aMAPK, (C) Syk, (D) Src, and (E) Lck gene expression in controls (n¼7) and DED subjects (n¼8) via
CIC sampling. Data were analyzed by the DCT method. ****P < 0.0001 comparing controls with DED.
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eBioscience, Hatfield, United Kingdom) and human recombi-
nant IL-2 (10 ng/mL; Peprotech, Rocky Hill, NJ, USA). After 48-
hour incubation under control tissue culture conditions,
supernatants were collected, and IFN-c release was determined
by Sandwich ELISA (Duo-set; R&D Systems, Abingdon, United
Kingdom). IC50s were determined from the dose–response
curves.
LPS Activation of Monocyte-Derived Macrophages.
CD14þ cells were isolated from human PBMCs by positive
selection using magnetic beads. Cells were resuspended in
RPMI containing 10% FBS and cultured (378C, 5% CO2) in the
presence of human recombinant granulocyte-macrophage
colony-stimulating factor (100 ng/mL) for 12 to 14 days. They
were then harvested and resuspended (2 3 105 cells/mL),
dispensed into 96-well plates (100 lL/well), and allowed to
equilibrate for 2 hours. Test compound (0.1 to 1000 ng/mL) or
vehicle (DMSO, 0.5% v/v) was incubated with cells (2 hours)
before stimulation with LPS (10 ng/mL) for 24 hours.
Supernatants were collected for IL-8 and TNF-a analysis.
ELISA. All cytokines were measured using commercial
ELISA kits, according to manufacturers’ instructions.
Dose Response of TOP1362 on Hyperosmolar-
Stressed Chang Cells. To assess the effect of TOP1362
treatment on p38a gene expression, Chang cells were seeded
and grown as above. These cells were exposed to a
hyperosmolar solution of complete media containing NaCl
(100 mM) for 6 hours, in the presence and absence of serial
dilutions of TOP1362 (0.01, 0.1, and 1.0 lg/mL). All serial
dilutions were made in 0.5% DMSO, and controls (vehicle
alone) contained complete media and 0.5% DMSO. Cells were
preincubated with TOP1362 (or vehicle) for 2 hours prior to
hyperosmolar stress. Gene expression levels of p38a in NSKI
hyperosmolar-stressed Chang cells were determined by qPCR
assays, results were analyzed using the DCT method,
2(DCT) ¼ (CT target gene – CT GAPDH), and GAPDH was the
chosen housekeeping gene to which p38a was normalized.
Rat Endotoxin-Induced Uveitis
Endotoxin-induced uveitis (EIU)47 was induced in male Lewis
rats (6 to 8 weeks old; Charles River UK Limited, Margate,
United Kingdom) through a single intravitreal administration of
100 ng/animal of LPS (E. coli 0111:B4, prepared in PBS; Sigma-
Aldrich, Gillingham, United Kingdom) into the right vitreous
humor (5-lL dose volume) using a 32-gauge needle. Control
rats were injected with PBS. Nonfasted rats were administered
a solution of TOP1362, dexamethasone, or vehicle (20%
hydroxypropyl-b-cyclodextrin, 0.1% hydroxypropyl methylcel-
lulose, 0.01% benzalkonium chloride, 0.05% EDTA, 0.7%
sodium chloride in deionized water) by topical administration
onto the right eye (10 lL) at 1, 0, 1, 2, and 4 hours with
respect to the LPS administration. In a separate time course
experiment, TOP1362 administration took place at the
different times (see Fig. 7A). Six hours after LPS dosing,
animals were euthanized by overdose with pentobarbitone (via
cardiac puncture). To measure cellular infiltration, 10 lL
aqueous humor was collected from the right eye of the rats
immediately after euthanasia by puncture of the anterior
chamber using a 32-gauge needle under a surgical microscope.
The aqueous humor collected was diluted in 20 lL PBS, and
FIGURE 2. (A) IL-1b, (B) IL-8, (C) MCP-1, and (D) MMP-9 gene expression in controls and DED subjects. Data were analyzed by the DCT method,
where target gene expression was standardized to a GAPDH housekeeping gene. ***P < 0.001 and ****P < 0.0001 comparing controls with DED.
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total cell counts were measured immediately using a Countess
automated cell counter (Invitrogen), with data being reported
as total cell numbers per milliliter. Cytokine analysis was
performed on eye homogenate. Following collection of the
aqueous humor, the right eye was enucleated and then
dissected into front and back sections around the lens. Each
section was weighed and homogenized in 500 lL sterile PBS
followed by 20 minutes centrifugation at 12,000 rpm at 48C.
The resulting supernatant was divided into three aliquots and
stored at808C until analysis, wherein levels of IL-1b, IL-6, and
MCP-1 were measured in duplicate using ELISA quantikine
assays (R&D Systems), as per the manufacturer’s instructions.
All work adhered to the ARVO Statement for the Use of Animals





was prepared as described previously.48 Z-lyte assay materials
and heat-inactivated FBS were obtained from Invitrogen.
Lymphoprep was obtained from Alere Limited (Stockport,
United Kingdom). Anti-CD3 and anti-CD28 antibodies were
supplied by eBioscience and BD Bioscience (Oxford, United
Kingdom), respectively. ELISA kits were acquired from R&D
Systems. All other reagents were obtained from Sigma-Aldrich.
RESULTS
Upregulation of p38a MAPK, Syk, Src, and Lck
Gene Expression in DED CIC Samples
qPCR analysis was performed to quantify target gene expres-
sion differences between conjunctival cells from controls (n¼
7) and DED (n ¼ 8) subjects, using CIC for sample retrieval.
The assays, standardized to GAPDH housekeeping gene,
revealed significant upregulation of p38a MAPK, Syk, Src,
and Lck genes in subjects with DED versus control subjects
(Fig. 1).
Increased IL-1b, IL-8, MCP-1, and MMP-9 Gene
Expression in Human CIC Samples
In subjects where there was sufficient mRNA remaining from
the kinase study, qPCR analysis was performed to quantify
cytokine and MMP-9 gene expression differences between
controls (n ¼ 3) and DED (n ¼ 3) subjects. Consistent with
reports in the literature, inflammatory markers IL-1b,15,19 IL-
8,19 MCP-1,16 and MMP-924 were significantly upregulated in
individuals with DED compared with control subjects (Fig. 2).
TOP1362 Potently Inhibits p38a, Syk, Src, and Lck
In Vitro
TOP1362 displayed high affinity to the target kinases p38a,
Syk, and Lck in competition binding and ligand dissociation
assays (Table 3) with dissociation constants (Kd) of 3.7 to 26
nM. The potent binding observed in these assays translated
into strong inhibitory activity in ATP-dependent substrate
phosphorylation assays, where TOP1362 inhibited all three
kinases examined (p38a, Syk, and Src) with nanomolar IC50s.
TOP1362 Concentration-Dependently Lowers p38a
Expression in Hyperosmolar-Stressed Chang
Conjunctival Epithelial Cells
qPCR assays were carried out to assess the expression levels of
the p38a gene in Chang cells following hyperosmolar stress.
Stress was induced using sodium chloride (100 and 400 mM) or
sucrose (200 and 400 mM), for 6 hours, versus untreated
control cells. After 6-hour treatment, both concentrations of
sodium chloride and the higher concentration of sucrose
significantly upregulated p38a gene expression in Chang cells
(Fig. 3A). It was observed, however, that the samples treated
with the higher concentration (400 mM) of sodium chloride
and sucrose had increased cell detachment and cell death.
Therefore, 100 mM sodium chloride was selected for the NSKI
studies.
The ability of TOP1362 to attenuate the upregulation of
p38a gene expression in Chang cells exposed to a hyperos-
molar stress for 6 hours was evaluated. At 0.1 and 1 lg/mL,
TOP1362 significantly downregulated p38a gene expression in
FIGURE 3. (A) Expression of p38a in hyperosmolar-stressed Chang
cells and (B) concentration-dependent inhibition by TOP1362 of 100
mM sodium chloride–induced p38a expression at 6 hours. Data were
analyzed by the DCT method, where target gene expression was
standardized to the housekeeping gene GAPDH. Assays were carried
out in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001.
TABLE 3. In Vitro Activities (nM) of NSKI TOP1362 at p38a, Syk, Src,
and Lck Kinases
Assay p38a Syk Src Lck
Ligand dissociation (Kd) 26 18 ND 3.7
Substrate phosphorylation (IC50) 137 314 32 ND
ND, not determined.
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sodium chloride stimulated Chang cells, whereas no effect was
seen at 0.01 lg/mL (Fig. 3B).
Inhibitory Effects of TOP1362 on Innate and
Adaptive Cellular Responses
Dry eye inflammation involves the interplay of innate and
adaptive immune mechanisms within the ocular sur-
face.12,42,49 As a model of innate immunity, PBMCs were
stimulated with LPS, leading to marked IL-8 release (15,700 6
1500 pg/mL). In contrast to the corticosteroid budesonide,
JAK inhibitor tofacitinib and DED treatment CsA, TOP1362
produced concentration-dependent (0.1 to 1000 ng/mL),
potent, and maximal (100%) inhibition of LPS-stimulated IL-
8 release (Fig. 4). Furthermore, TOP1362 and budesonide
both inhibited LPS-stimulated TNF-a release from PBMCs with
single-digit nM IC50s (Table 4), in contrast to tofacitinib and
CsA, which did not inhibit release of this cytokine. A similar
profile was observed in LPS-stimulated primary human
macrophages, with TOP1362 achieving potent, maximal
inhibition of IL-8 and TNF-a release, budesonide acting most
effectively on TNF-a, and tofacitinib and CsA being largely
inactive.
To model the adaptive immune response, PBMCs were
stimulated with (1) anti-CD3/anti-CD28 and (2) anti-CD3/IL-2
to activate the T-cell population, resulting in release of IFN-c of
(1) 16100 6 5900 pg/mL and (2) 2010 6 480 pg/mL. In both
cases, TOP1362 achieved maximal inhibition of IFN-c release
with low nanomolar IC50s (Table 4). The other agents
evaluated also inhibited IFN-c release, although less potently
than TOP1362, with the exception of budesonide inhibition of
IFN-c secretion from anti-CD3/IL-2–activated PBMCs.
FIGURE 4. Inhibition of LPS-stimulated IL-8 release from PBMCs by (A) TOP1362, (B) budesonide, (C) tofacitinib, and (D) CsA. Associated IC50
values are given in Table 4.
TABLE 4. Inhibition of Cytokine Release, Induced by Various Stimuli, From PBMCs and Primary Macrophages by TOP1362, Budesonide, Tofacitinib,
and CsA
Cell Type Stimulus Cytokine
IC50s (nM)
TOP1362 Budesonide Tofacitinib CsA
PBMC LPS IL-8 1.9 >2300 >3200 >830
PBMC LPS TNF-a 0.8 6.0 >3200 >830
Primary macrophage LPS IL-8 9.1 >580 >800 NT
Primary macrophage LPS TNF-a 2.1 11 >800 NT
PBMC a-CD3/CD28 IFN-c 12 >2300 607 51
PBMC a-CD3/IL-2 IFN-c 1.6 1.2 56 9.2
NT, not tested.
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TOP1362 Is Efficacious in the Rat EIU Model
Intravitreal injection of LPS into the aqueous humor of male
Lewis rats increased concentrations of the inflammatory
markers IL-1b, IL-6, and MCP-1 in both the anterior and
posterior segments of the eye (Fig. 5). Topical administration of
0.1% TOP1362 eye drops at 1, 0, 1, 2, and 4 hours with
respect to the LPS administration attenuated the increases in
these cytokines as effectively as an equivalent 0.1% dose of the
corticosteroid dexamethasone (administered under the same
dosing regimen).
In a separate EIU experiment, TOP1362 eye drops
concentration-dependently lowered inflammatory cell infiltra-
tion into the aqueous humor (Fig. 6A). The reduction in
inflammatory cell infiltrate observed correlated with decreases
in IL-1b levels in both the anterior and posterior segments of
the eye and was dependent on the number of instillations of
TOP1362 (Fig. 7).
DISCUSSION
Despite recent additions to the ophthalmologist’s therapeutic
options (e.g., lifitegrast), the treatment of DED remains a
significant unmet medical need,10 and new therapies are
urgently required to treat this debilitating condition character-
ized by chronic inflammation.50 Given their potent and broad-
ranging anti-inflammatory effects in a wide range of cell types
with key roles in various inflammatory disorders (UC,34
COPD,35 and arthritis36), we hypothesized that NSKIs could
address the poorly served medical need of DED. Although the
initial ocular surface insult in DED can be multifactorial (low
FIGURE 5. In LPS-exposed rats, following topical ocular administration, 0.1% TOP1362 solution reduces IL-1b (A, D), IL-6 (B, E), and MCP-1 (C, F)
levels in the anterior (A–C) and posterior (D–F) segment of the eye as effectively as an equivalent, and maximally effective, dose of dexamethasone.
*P < 0.05 relative to vehicle control.
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tear volume, poor tear quality, contact lens use), the vicious
cycle of chronic disease progression appears to be similar in
most cases, with innate immune pathways becoming activated
initially. Subsequently, an adaptive immune response, which
becomes dysregulated ultimately, is triggered.12 Intracellular
kinases are involved in signaling cascades of both the innate
and adaptive immune responses. To the best of our knowledge,
however, no investigative studies in DED patients have been
conducted to determine the expression of kinases in disease.
Here, we demonstrate, for the first time, that the NSKI targets
p38a, Syk, Lck, and Src are significantly upregulated in cells
obtained from the ocular surface of DED patients compared
with those of healthy controls. Moreover, we show that this
upregulation is associated with increases in the inflammatory
cytokines IL-1b, IL-8, and MCP-1, as well as in the inflamma-
tory mediator MMP-9. Due to limited patient samples, only
p38a phosphorylation was investigated by immunohistochem-
istry and found to be upregulated in patient conjunctival cells
compared with healthy volunteers (Supplementary Materials).
The role of p38a in DED pathogenesis is further supported by
its upregulation in a conjunctival cell line (Chang cells) in
FIGURE 6. Following topical ocular administration, in the rat EIU
model, TOP1362 solution concentration-dependently reduced (A) the
total number of cells in the aqueous humor, as well as IL-1b levels in
the anterior (B) and posterior (C) segments of the eye. *P < 0.05 and
**P < 0.01 relative to vehicle control.
FIGURE 7. Anti-inflammatory efficacy of topical 0.1% TOP1362
solution in the rat EIU model employing different treatment regimens.
(A) Treatment regimens used with timings expressed relative to LPS
administration at T ¼ 0 hours: V, vehicle administered; T, TOP1362
administered (single 40-lL drop); –, no dosing. (B–D) Effect of the
different treatment regimens on the total number of cells in the
aqueous humor (B), as well as anterior (C) and posterior (D) IL-1b
levels. *P < 0.05 and **P < 0.01 relative to vehicle control.
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response to hyperosmolar challenge, a response that can be
inhibited by treatment with NSKI TOP1362.
In terms of cellular expression, p38a and Src are expressed
ubiquitously, whereas Syk and Lck are primarily expressed in
lymphocytes. Thus, the increased expression of Syk and Lck
observed in DED patients may be a reflection of a raised
inflammatory infiltrate into conjunctival tissue. Although
inhibitors targeting a single kinase, such as p38a, have been
proposed as potential therapies for DED,51 these selective
agents have displayed disappointing efficacy in clinical trials
in other inflammatory disorders.52 To obtain superior efficacy
in the clinic, polypharmacology53—using a broader, multi-
targeted approach—is emerging as a new drug treatment
paradigm for treating diseases of complex pathophysiology,
such as DED and UC.
As a consequence of its polypharmacologic mode of action,
NSKI TOP1362 demonstrated wide-ranging and potent inhibi-
tion of cytokine release from several cell types induced by
various different stimuli. Underscoring the potential of NSKIs
as novel DED therapies, the inhibition elicited by TOP1362
was, in many cases, superior to that acheived by the topical
corticosteroid budesonide. Furthermore, TOP1362 provided a
much broader, and more potent, inhibition of cytokine release
compared with both CsA, the active pharmaceutical ingredient
in the approved DED therapy Restasis,54 and tofacitinib, a JAK
inhibitor with some evidence of efficacy in the clinic.30
Further evidence for the potential of TOP1362 in inflamma-
tory eye disease was furnished by an EIU experiment in rats. The
EIU model has been used47 to determine the potential
therapeutic efficacy of drugs that could prevent or ameliorate
ocular inflammation. In this model, following topical adminis-
tration, TOP1362 dose-dependently attenuated the increases in
inflammatory cell infiltration and cytokines, which are shown
here to be upregulated in DED patients. Interestingly, the
reduction of cytokine release in the posterior segment of the eye
was comparable to that elicited in the anterior segment,
indicating that TOP1362 can reach the back of the eye,
presumably via the trans-scleral route,55 and highlighting the
potential for treating posterior segment disorders. Importantly,
the efficacy elicited by 0.1% TOP1362 in this experiment was
almost identical to that produced by 0.1% dexamethasone over
several separate EIU studies. Topical corticosteroids, such as
methylprednisolone56 or loteprednol etabonate,57 are arguably
the most effective therapies for treating DED, but they are
typically administered for only a limited period of time, because
they are associated with significant side effects (e.g., bacterial
infection, IOP elevation, and cataract formation) after prolonged
use. Interestingly, in a cellular setting, topical corticosteroid was
more broad acting than either CsA or tofacitinib and was most
similar, in terms of potency and breadth of activity, to TOP1362.
The breadth of activity achieved by TOP1362 stems from its
ability to simultaneously target multiple key signalling kinases
involved in both innate and adaptive immune pathways and
highlights the potential of NSKIs to treat inflammatory disorders
of complex pathophysiology, such as DED. In this regard,
optimization of TOP1362 gave rise to TOP1630, an NSKI that
has recently provided positive results in a phase 2a clinical trial
in DED (clinical study reference NCT03088605).
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